Statistics

Total Visits

Views
Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)62

Select a period of time:

Number of views in the range

Views
Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)34

Views

Views
November 20242
December 20241
January 20252
February 202510
March 202515
April 20253
May 20251
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore18
United States14
Spain1
United Kingdom1
 

Top cities views

Views
Council Bluffs1
Los Angeles1